IL6R and COVID-19: Our group has previously reported that the humoral immune response following two vaccine doses against COVID-19 is severely impaired with rituximab treatment, reduced with abatacept, and to some extent also reduced with interleukin-6 receptor inhibitors (IL6ri) in patients with IRD compared to controls (19).